We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




MSI Tumor Analysis Implicates Lynch Syndrome in Cancer Types

By LabMedica International staff writers
Posted on 19 Jun 2018
Print article
Image: An endometrial carcinoma showing loss of nuclear expression of MSH2. The lymphocytes and stromal cells should stain positive and represent an internal positive control (Photo courtesy of Memorial Sloan Kettering Cancer Center).
Image: An endometrial carcinoma showing loss of nuclear expression of MSH2. The lymphocytes and stromal cells should stain positive and represent an internal positive control (Photo courtesy of Memorial Sloan Kettering Cancer Center).
A new pan-cancer analysis suggests that there may be a benefit to doing germline testing for Lynch syndrome in advanced cancer patients who have high microsatellite instability (MSI) in their tumors.

Lynch syndrome mutations have turned up in the germline of individuals with prostate cancer, sarcoma, mesothelioma, and other cancer types not linked to the condition in the past. Nearly half of the non- colorectal cancer/endometrial cancer cases with Lynch gene mutations and MSI-high (MSI-H) or intermediate/indeterminate (MSI-I) status came from cases that would not meet the current criteria for Lynch syndrome testing.

Scientists at Memorial Sloan-Kettering Cancer Center (New York, NY, USA) carried out a prospective study involving 15,045 cancer patients who had their matched tumor and normal samples analyzed on MSK-IMPACT, an FDA-authorized, next-generation sequencing-based pipeline for detecting MSI as well as mutations in hundreds of tumor-associated genes. After clustering the tumors based on their MSI scores, the team overlaid information on Lynch syndrome gene mutations in the patients' germlines, demonstrating that the autosomal dominant cancer predisposition syndrome appears to be dramatically over-represented in individuals with tumors in the MSI high (MSI-H) and intermediate/indeterminate (MSI-I) group, but rare in individuals with microsatellite stable (MSS) tumors.

The team found that half of the tumors that occurred in the apparent Lynch syndrome individuals with MSI-H or MSI-I tumors were colorectal or endometrial, the cancer types that are best known in Lynch syndrome. The team was also able to determine whether those MSI classifications coincided with the presence of pathogenic or likely pathogenic changes in Lynch syndrome-related mutations in the Lynch syndrome-related DNA repair genes MLH1, MSH2, MSH6, PMS2, and EPCAM. The investigators reported that more than 16% of the 326 tumors classified as MSI-H contained Lynch syndrome-related mutations, as did 1.9% of the 699 tumors designated as MSI-I. In contrast, only 0.3% of the 14,020 MSS tumors contained the telltale Lynch syndrome mutations in MLH1, MSH2, MSH6, PMS2, or EPCAM, on par with the 0.3% Lynch syndrome prevalence rate previously reported in the general population.

Zsofia Kinga Stadler, MD, a medical oncologist and senior author of the study, said, “The result is an increased ability to recognize Lynch syndrome, not only in our cancer patients, but also in at-risk family members who may benefit from genetic testing for Lynch and subsequent enhanced cancer surveillance and risk reduction measures.” The study was presented at the American Society of Clinical Oncology annual meeting held June 1-5, 2018, in Chicago, IL, USA.

Related Links:
Memorial Sloan-Kettering Cancer Center

Gold Member
Turnkey Packaging Solution
HLX
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Thyroxine ELISA
T4 ELISA
New
Newborn Screening Test
NeoMass AAAC 3.0

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.